Psoriatic arthritis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]

Overview

Essential measures for the secondary prevention of psoriatic arthritis include calcium and vitamin D supplementation to prevent drug associated osteoporosis. To decrease the risk of cardiovascular complications and to prevent recurrent episodes effective measures include exercise, smoking cessation, and dietary control.

Secondary prevention

The following measures may be helpful for the secondary prevention of psoriatic arthritis:
- Protection of bone is essential due to the prolonged use of glucocorticoids and DMARDs to prevent drug induced osteoporosis.
- Supplemental intake of calcium 1000 to 1200 mg/day and vitamin D 600 to 800 IU/day is recommended for patients using prolonged glucocorticoids.^[1]
Patients are monitored regularly for disease activity, drug efficacy, adverse effects and associated comorbid conditions.^[2]
The following measures are helpful to prevent cardiovascular complications associated with psoriatic arthritis.^[3]
- Smoking cessation
- Dietary control to prevent hyperlipidemia, hypertension, and diabetes mellitus.
- Exercise
- Patient education

References

↑ Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (August 2017). “2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis”. Arthritis Rheumatol. 69 (8): 1521–1537. doi:10.1002/art.40137. PMID 28585373.
↑ Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W (January 2004). “Assessment of patients with psoriatic arthritis: a review of currently available measures”. Arthritis Rheum. 50 (1): 24–35. doi:10.1002/art.11417. PMID 14730596.
↑ Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT (January 2017). “EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update”. Ann. Rheum. Dis. 76 (1): 17–28. doi:10.1136/annrheumdis-2016-209775. PMID 27697765.

Template:WH Template:WS

[pmid28585373-1] Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (August 2017). “2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis”. Arthritis Rheumatol. 69 (8): 1521–1537. doi:10.1002/art.40137. PMID 28585373.

[pmid14730596-2] Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W (January 2004). “Assessment of patients with psoriatic arthritis: a review of currently available measures”. Arthritis Rheum. 50 (1): 24–35. doi:10.1002/art.11417. PMID 14730596.

[pmid27697765-3] Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT (January 2017). “EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update”. Ann. Rheum. Dis. 76 (1): 17–28. doi:10.1136/annrheumdis-2016-209775. PMID 27697765.

[1]

[2]

[3]

Psoriatic arthritis secondary prevention

Overview

Secondary prevention

References

Looking for the patient version?